EpiPen Maker Mylan Settles For $485 Million In Medicaid Dispute
The federal Medicaid program had accused Mylan of underpaying required rebates for the EpiPen, which is used to reverse serious allergic reactions. The company said it committed no wrongdoing.
No comments:
Post a Comment